Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Immunotherapy of brain metastases: breaking a "dogma".

Di Giacomo AM, Valente M, Cerase A, Lofiego MF, Piazzini F, Calabrò L, Gambale E, Covre A, Maio M.

J Exp Clin Cancer Res. 2019 Oct 17;38(1):419. doi: 10.1186/s13046-019-1426-2. Review.

2.

Immunotherapy targeting immune check-point(s) in brain metastases.

Di Giacomo AM, Valente M, Covre A, Danielli R, Maio M.

Cytokine Growth Factor Rev. 2017 Aug;36:33-38. doi: 10.1016/j.cytogfr.2017.07.002. Epub 2017 Jul 13. Review.

PMID:
28736183
3.

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.

Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, Brahmer J, Lipson E, Sharfman W, Hammers H, Naidoo J, Bettegowda C, Lim M, Redmond KJ.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):916-925. doi: 10.1016/j.ijrobp.2017.11.041. Epub 2017 Dec 5.

PMID:
29485071
4.

Management of Brain Metastases in the New Era of Checkpoint Inhibition.

Lauko A, Thapa B, Venur VA, Ahluwalia MS.

Curr Neurol Neurosci Rep. 2018 Aug 18;18(10):70. doi: 10.1007/s11910-018-0877-8. Review.

PMID:
30121715
5.

Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.

Berghoff AS, Venur VA, Preusser M, Ahluwalia MS.

Am Soc Clin Oncol Educ Book. 2016;35:e116-22. doi: 10.14694/EDBK_100005. Review.

6.

Systemic treatments for metastatic cutaneous melanoma.

Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S.

Cochrane Database Syst Rev. 2018 Feb 6;2:CD011123. doi: 10.1002/14651858.CD011123.pub2. Review.

7.

Immune Checkpoint Inhibitors for Brain Metastases.

Tan AC, Heimberger AB, Menzies AM, Pavlakis N, Khasraw M.

Curr Oncol Rep. 2017 Jun;19(6):38. doi: 10.1007/s11912-017-0596-3. Review.

PMID:
28417311
8.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

9.

A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin.

Kattan J, Rassy EE, Assi T, Bakouny Z, Pavlidis N.

Crit Rev Oncol Hematol. 2018 Oct;130:60-69. doi: 10.1016/j.critrevonc.2018.08.001. Epub 2018 Aug 7. Review.

PMID:
30196913
10.

Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment.

El Rassy E, Botticella A, Kattan J, Le PĂ©choux C, Besse B, Hendriks L.

Cancer Treat Rev. 2018 Jul;68:69-79. doi: 10.1016/j.ctrv.2018.05.015. Epub 2018 May 31. Review.

11.

Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study.

Shepard MJ, Xu Z, Donahue J, Eluvathingal Muttikkal TJ, Cordeiro D, Hansen L, Mohammed N, Gentzler RD, Larner J, Fadul CE, Sheehan JP.

J Neurosurg. 2019 Jul 26:1-8. doi: 10.3171/2019.4.JNS19822. [Epub ahead of print]

PMID:
31349225
12.

Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?

Zhang C, Yu D.

Cell Biosci. 2019 Oct 7;9:82. doi: 10.1186/s13578-019-0349-0. eCollection 2019. Review.

13.

Cancer immunotherapy in patients with brain metastases.

Caponnetto S, Draghi A, Borch TH, Nuti M, Cortesi E, Svane IM, Donia M.

Cancer Immunol Immunother. 2018 May;67(5):703-711. doi: 10.1007/s00262-018-2146-8. Epub 2018 Mar 8. Review.

PMID:
29520474
14.

Management of single brain metastasis: a practice guideline.

Mintz A, Perry J, Spithoff K, Chambers A, Laperriere N.

Curr Oncol. 2007 Aug;14(4):131-43.

15.

The biology and therapeutic management of melanoma brain metastases.

Abate-Daga D, Ramello MC, Smalley I, Forsyth PA, Smalley KSM.

Biochem Pharmacol. 2018 Jul;153:35-45. doi: 10.1016/j.bcp.2017.12.019. Epub 2017 Dec 24. Review.

16.

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases.

Lehrer EJ, McGee HM, Peterson JL, Vallow L, Ruiz-Garcia H, Zaorsky NG, Sharma S, Trifiletti DM.

Int J Mol Sci. 2018 Oct 7;19(10). pii: E3054. doi: 10.3390/ijms19103054. Review.

17.

Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.

Alvarez-Breckenridge C, Giobbie-Hurder A, Gill CM, Bertalan M, Stocking J, Kaplan A, Nayyar N, Lawrence DP, Flaherty KT, Shih HA, Oh K, Batchelor TT, Cahill DP, Sullivan R, Brastianos PK.

Oncologist. 2019 May;24(5):671-679. doi: 10.1634/theoncologist.2018-0306. Epub 2019 Feb 22.

PMID:
30796152
18.

Radiotherapy and immune checkpoints inhibitors for advanced melanoma.

Filippi AR, Fava P, Badellino S, Astrua C, Ricardi U, Quaglino P.

Radiother Oncol. 2016 Jul;120(1):1-12. doi: 10.1016/j.radonc.2016.06.003. Epub 2016 Jun 23. Review.

PMID:
27345592
19.

Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, Progression, and Pseudoprogression.

Galldiks N, Kocher M, Ceccon G, Werner JM, Brunn A, Deckert M, Pope WB, Soffietti R, Le Rhun E, Weller M, Tonn JC, Fink GR, Langen KJ.

Neuro Oncol. 2019 Aug 22. pii: noz147. doi: 10.1093/neuonc/noz147. [Epub ahead of print]

PMID:
31437274
20.

Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?

Franceschini D, Franzese C, Navarria P, Ascolese AM, De Rose F, Del Vecchio M, Santoro A, Scorsetti M.

Cancer Treat Rev. 2016 Nov;50:1-8. doi: 10.1016/j.ctrv.2016.08.003. Epub 2016 Aug 18. Review.

PMID:
27566962

Supplemental Content

Support Center